江苏吉贝尔药业股份有限公司 关于仲裁事项进展的公告

Core Viewpoint - The arbitration case involving Jiangsu Jibeier Pharmaceutical Co., Ltd. and Shenzhen Huada Ocean Technology Co., Ltd. has reached a significant stage, with the Shanghai First Intermediate People's Court rejecting Huada Ocean's application to overturn the arbitration ruling [2][3][5] Group 1: Arbitration Case Overview - The arbitration was initiated by Jiangsu Jibeier Pharmaceutical against Huada Ocean regarding a share repurchase dispute related to Shenzhen Huahong Ocean Biological Pharmaceutical Co., Ltd. [2] - The Shanghai International Economic and Trade Arbitration Commission issued a ruling (No. 3816) on this matter, which is detailed in the company's announcements on the Shanghai Stock Exchange [2] Group 2: Recent Developments - Huada Ocean has filed an application to the Shanghai First Intermediate People's Court to annul the arbitration ruling, but the court has recently issued a civil ruling rejecting this application [2][3][5] - The ruling from the arbitration commission is considered final, and its impact on the company's financial performance will depend on the actual execution of the ruling [3][5]